
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
Navitas Life Sciences announced the acquisition of US based niche full service CRO and health research company, KAI Research Inc. KAI Research brings offerings in three key areas to the table – Clinical Trial Management, Clinical Research Consultation, and Data Management & Standardization.
For more details on the acquisition, click







